For Immediate Release, August 25, 2020.

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a
pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs today announced that it has completed the synthesis of four
different potential inhibitors of Coronavirus protease. These compounds are based on the
technology described in the Company’s recently filed patent application covering small
molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the
causative agent of COVID-19. Next, Sunshine will evaluate the binding affinity of these
molecules to the SARS-CoV-2 papain-like protease (PLpro), one of two virus encoded
proteases essential for viral replication. In addition to cleaving the virus encoded polyprotein at
three different sites to generate mature virus proteins, PLpro also cleaves certain host proteins
resulting in suppression of the innate immune response thereby allowing the virus to multiply
unhindered. Based on the binding affinity results, Sunshine will select a lead compound for
further Anti-Coronavirus drug development.

About Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company focused on the research, development, and
commercialization of oncology and antiviral drugs. In addition, to working on the development of
a treatment for COVID-19, Sunshine biopharma is engaged in the development Adva-27a, a
unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of
Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells,
Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for
Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General
Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual
property pertaining to Adva-27a and the Coronavirus protease inhibitors under development.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals,
future financial conditions, future collaboration agreements, the success of the Company’s development,
events conditioned on stockholder or other approval, or otherwise as to future events, such statements
are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to
certain risks and uncertainties that could cause actual results to differ materially from the statements

For Additional Information:
Sunshine Biopharma, Inc.

Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]